Short answer: The Egrifta SV label gives one dose: 1.4 mg injected under the skin of the abdomen once daily. There is no starting dose or step-up schedule. Each 2 mg vial is single-dose: the dose is given right after the vial is prepared and anything left is thrown away. Injection sites are rotated around the abdomen, avoiding scar tissue, bruises and the navel.
This is what the FDA label says. Follow your prescriber. Your prescriber may use a different dose or pace than the label's standard schedule.
What Egrifta SV is approved for: Egrifta SV is approved to reduce excess abdominal fat in adults with HIV who have lipodystrophy. The label says it is not for weight loss management, its long-term heart and blood vessel safety has not been established, and there are no data that it improves how well people take their HIV medicines (section 1).
Source
EGRIFTA SV (tesamorelin) for injection, prescribing information and Patient Information. Theratechnologies. DailyMed, version published July 31, 2026. DailyMed setid 3d783378-b02d-4f19-99dd-0fc91a042224
Egrifta SV is injected under the skin (subcutaneously) into the abdomen once a day. The label says to rotate injection sites to different areas of the abdomen and not to inject into scar tissue, bruises or the navel (section 2.1).
It comes as a 2 mg single-dose vial with Sterile Water for Injection as the diluent (section 3). The dose is given immediately after the vial is prepared; any unused solution is thrown away, and prepared solution is never stored, frozen or refrigerated (section 2.2). The label points patients to the Instructions for Use in the Medication Box.
The Patient Information says never to share an Egrifta SV syringe or needles with anyone, even if the needle has been changed.
The table below is the label's schedule, from the Dosage and Administration section. Numbers are copied exactly; the section is in brackets.
| Item | What the label says |
|---|---|
| Dose | 1.4 mg |
| How often | Once daily |
| Route | Subcutaneous (under the skin) |
| Where | Abdomen, rotating to different areas of the abdomen |
| Avoid | Scar tissue, bruises or the navel |
| Vial | 2 mg single-dose vial; given immediately after it is prepared, unused solution thrown away |
| Titration | None given; the label lists a single dose |
The dose of Egrifta SV is 1.4 mg injected subcutaneously once daily. The label gives no other dose and no step-up schedule.
The label's dosing applies only to the 2 mg per vial formulation. It says the tesamorelin formulations and strengths differ in dosage, the number of vials needed for a dose, preparation and storage.
IGF-1 levels are monitored during treatment. Stopping is considered in people whose IGF-1 stays high (for example above 3 SDS), particularly if the response is not robust.
Glucose status is checked before starting and periodically during treatment. If glucose intolerance or diabetes develops, stopping is considered in people without a clear response. People with diabetes may need changes to their diabetes medicines (section 17).
Because long-term heart safety is not established, the label says to weigh the risk and benefit of continuing in people who have not had a reduction in visceral (deep belly) fat.
Stopping Egrifta SV is considered in critically ill patients.
Egrifta SV is not used during pregnancy; the label says to stop it if pregnancy occurs (section 17). Mothers on Egrifta SV are told not to breastfeed.
The label gives no missed-dose instruction.
The Egrifta SV dosing covers only the 2 mg per vial formulation. For the 1 mg per vial formulation, the label points to the EGRIFTA prescribing information, because the formulations differ in dosage, number of vials per dose, preparation and storage.
In Dose Track you set up Egrifta SV as a protocol with the dose and schedule your prescriber gave you. A protocol can hold dose steps, each with its own dose and length in days or weeks, so a step-up plan like the one on the label can be entered once and the app moves to the next step on its own. Reminders follow the schedule, and every dose is logged with the date and time, so you can see which step you are on and when your last dose was. The app follows what you enter; it does not choose or change a dose.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.